Skip to content

Home Search Authors Pakistan News Saved

SciRah

SciRah does not host or store research papers. Results come live from free, official scholarly APIs, and every paper links back to its original source.

Data sources

OpenAlex
Semantic Scholar
Crossref
CORE
arXiv
PubMed

Privacy policy Terms of service

N. Senzer · SciRah

Researcher profile · Semantic Scholar

N. Senzer

Share profile

N. Senzer — researcher profile on SciRah

h-index: 52
Works: 231
Citations: 13K

Most-cited papers

Talimogene Laherparepvec Improves Durable Response Rate in Patients With Advanced Melanoma.
R. Andtbacka, H. Kaufman, F. Collichio, T. Amatruda +25 more
2015Journal of Clinical Oncology2,369 citations
Semantic Scholar
A phase I study of telomerase-specific replication competent oncolytic adenovirus (telomelysin) for various solid tumors.
J. Nemunaitis, A. Tong, M. Nemunaitis, N. Senzer +11 more
2010Molecular Therapy272 citations Open access
Semantic Scholar
Phase I study of a systemically delivered p53 nanoparticle in advanced solid tumors.
N. Senzer, J. Nemunaitis, Derek Nemunaitis, C. Bedell +6 more
2013Molecular Therapy244 citations Open access
Semantic Scholar
Bromodomain and extra-terminal motif inhibitors: a review of preclinical and clinical advances in cancer therapy
Ali J Alqahtani, Khalil Choucair, M. Ashraf, Danae M. Hammouda +4 more
2019Future Science OA225 citations Open access
Semantic Scholar
OPTiM: A randomized phase III trial of talimogene laherparepvec (T-VEC) versus subcutaneous (SC) granulocyte-macrophage colony-stimulating factor (GM-CSF) for the treatment (tx) of unresected stage IIIB/C and IV melanoma.
H. Kaufman, R. Andtbacka, F. Collichio, T. Amatruda +10 more
2013Journal of Clinical Oncology171 citations
Semantic Scholar
Phase I Clinical Study of Seneca Valley Virus (SVV-001), a Replication-Competent Picornavirus, in Advanced Solid Tumors with Neuroendocrine Features
C. Rudin, J. Poirier, N. Senzer, J. Stephenson +5 more
2011Clinical Cancer Research168 citations Open access
Semantic Scholar
RNA Interference and Cancer Therapy
Zhao-Hui Wang, D. Rao, N. Senzer, J. Nemunaitis
2011Pharmaceutical Research159 citations
Semantic Scholar
Phase I Trial of "bi-shRNAifurin/GMCSF DNA/Autologous Tumor Cell" Vaccine (FANG) in Advanced Cancer.
N. Senzer, M. Barve, J. Kuhn, A. Melnyk +22 more
2012Molecular Therapy148 citations Open access
Semantic Scholar
Tivantinib (ARQ 197), a selective inhibitor of MET, in patients with microphthalmia transcription factor–associated tumors
A. Wagner, J. Goldberg, S. G. DuBois, E. Choy +11 more
2012Cancer147 citations
Semantic Scholar
EUS or percutaneously guided intratumoral TNFerade biologic with 5-fluorouracil and radiotherapy for first-line treatment of locally advanced pancreatic cancer: a phase I/II study
J. Hecht, James Farrell, N. Senzer, J. Nemunaitis +14 more
2012Gastrointestinal Endoscopy136 citations Open access
Semantic Scholar
Phase I trial of "bi-shRNAi(furin)/GMCSF DNA/autologous tumor cell" vaccine (FANG) in advanced cancer.
N. Senzer, M. Barve, J. Kuhn, A. Melnyk +22 more
2012Molecular Therapy130 citations Open access
Semantic Scholar
Systemic versus local responses in melanoma patients treated with talimogene laherparepvec from a multi-institutional phase II study
H. Kaufman, T. Amatruda, T. Reid, R. Gonzalez +7 more
2016Journal of Immunotherapy for Cancer100 citations Open access
Semantic Scholar
Phase II study of Vigil® DNA engineered immunotherapy as maintenance in advanced stage ovarian cancer.
Jonathan C. Oh, M. Barve, C. Matthews, E. Koon +18 more
2016Gynecologic Oncology96 citations
Semantic Scholar
A Phase I Dose-Escalation Study of Tivantinib (ARQ 197) in Adult Patients with Metastatic Solid Tumors
L. Rosen, N. Senzer, T. Mekhail, R. Ganapathi +6 more
2011Clinical Cancer Research94 citations Open access
Semantic Scholar
A Phase-1b study of tivantinib (ARQ 197) in adult patients with hepatocellular carcinoma and cirrhosis
A. Santoro, M. Simonelli, C. Rodríguez-Lope, P. Zucali +9 more
2013British Journal of Cancer76 citations Open access
Semantic Scholar
A multicenter phase 1 study of PX-866 in combination with docetaxel in patients with advanced solid tumours
Daniel W Bowles, Wen W. Ma, N. Senzer, J. Brahmer +9 more
2013British Journal of Cancer65 citations Open access
Semantic Scholar
Oncolytic viruses for induction of anti-tumor immunity.
A. Tong, N. Senzer, V. Cerullo, N. Templeton +2 more
2012Current Pharmaceutical Biotechnology63 citations
Semantic Scholar
Three-year Follow up of GMCSF/bi-shRNA(furin) DNA-transfected Autologous Tumor Immunotherapy (Vigil) in Metastatic Advanced Ewing's Sarcoma.
Maurizio Ghisoli, M. Barve, R. Mennel, C. Lenarsky +7 more
2016Molecular Therapy62 citations Open access
Semantic Scholar
Phase I Trial of TGF-β2 Antisense GM-CSF Gene-Modified Autologous Tumor Cell (TAG) Vaccine
J. Olivares, Padmasini Kumar, Yang Yu, P. Maples +9 more
2011Clinical Cancer Research58 citations Open access
Semantic Scholar
Pilot Trial of FANG Immunotherapy in Ewing's Sarcoma
Maurizio Ghisoli, M. Barve, R. Schneider, R. Mennel +12 more
2015Molecular Therapy57 citations Open access
Semantic Scholar
Evofosfamide for the treatment of human papillomavirus-negative head and neck squamous cell carcinoma.
S. Jamieson, P. Tsai, Maria Kondratyev, Pratha Budhani +31 more
2018JCI Insight52 citations Open access
Semantic Scholar
Results of the X-PECT study: A phase III randomized double-blind, placebo-controlled study of perifosine plus capecitabine (P-CAP) versus placebo plus capecitabine (CAP) in patients (pts) with refractory metastatic colorectal cancer (mCRC).
J. Bendell, T. Ervin, N. Senzer, Donald A. Richards +7 more
2012Journal of Clinical Oncology52 citations
Semantic Scholar
Hereditary Inclusion Body Myopathy: Single Patient Response to Intravenous Dosing of GNE Gene Lipoplex
G. Nemunaitis, C. Jay, P. Maples, W. Gahl +12 more
2011Human Gene Therapy52 citations Open access
Semantic Scholar
Cancer of the Liver
J. Nemunaitis, M. Barve, D. Orr, J. Kuhn +11 more
201449 citations
Semantic Scholar
Phase I study of intravenously administered ATI-1123, a liposomal docetaxel formulation in patients with advanced solid tumors
D. Mahalingam, J. Nemunaitis, L. Malik, J. Sarantopoulos +10 more
2014Cancer Chemotherapy and Pharmacology46 citations
Semantic Scholar
Phase I evaluation of TNFerade biologic plus chemoradiotherapy before esophagectomy for locally advanced resectable esophageal cancer
K. Chang, T. Reid, N. Senzer, S. Swisher +4 more
2012Gastrointestinal Endoscopy46 citations Open access
Semantic Scholar
Preclinical Justification of pbi-shRNA EWS/FLI1 Lipoplex (LPX) Treatment for Ewing's Sarcoma
D. Rao, C. Jay, Zhao-Hui Wang, Xiuquan Luo +5 more
2016Molecular Therapy44 citations Open access
Semantic Scholar
In vivo Safety and Antitumor Efficacy of Bifunctional Small Hairpin RNAs Specific for the Human Stathmin 1 Oncoprotein
A. Phadke, C. Jay, Zhao-Hui Wang, Salina J. Chen +17 more
2011DNA and Cell Biology44 citations
Semantic Scholar
A Phase 2 Efficacy and Safety, Open-label, Multicenter Study of Imprime PGG Injection in Combination with Cetuximab in Patients with Stage IV KRAS-Mutant Colorectal Cancer
N. Segal, P. Gada, N. Senzer, M. Gargano +2 more
2016Clinical colorectal cancer43 citations Open access
Semantic Scholar
Long Term Follow Up: Phase I Trial of bi-shRNA furin/GMCSF DNA/Autologous Tumor Cell Immunotherapy (FANG) in Advanced Cancer
N. Senzer, M. Barve, J. Nemunaitis, J. Kuhn +12 more
201342 citations
Semantic Scholar
Phase I trial of intratumoral therapy using HF10, an oncolytic HSV-1, demonstrates safety in HSV+/HSV- patients with refractory and superficial cancers.
R. Ferris, N. Gross, J. Nemunaitis, R. Andtbacka +8 more
201434 citations
Semantic Scholar
Gemogenovatucel-T (Vigil) immunotherapy demonstrates clinical benefit in homologous recombination proficient (HRP) ovarian cancer.
R. Rocconi, B. Monk, Adam Walter, T. Herzog +9 more
2021Gynecologic Oncology33 citations
Semantic Scholar
PDX-1 Is a Therapeutic Target for Pancreatic Cancer, Insulinoma and Islet Neoplasia Using a Novel RNA Interference Platform
Shi-he Liu, D. Rao, J. Nemunaitis, N. Senzer +12 more
2012PLoS ONE32 citations Open access
Semantic Scholar
Final planned overall survival (OS) from OPTiM, a randomized Phase III trial of talimogene laherparepvec (T-VEC) versus GM-CSF for the treatment of unresected stage IIIB/C/IV melanoma (NCT00769704)
R. Andtbacka, F. Collichio, T. Amatruda, N. Senzer +12 more
2014Journal of Immunotherapy for Cancer28 citations Open access
Semantic Scholar
RNA interference and personalized cancer therapy.
D. Rao, Zhao-Hui Wang, N. Senzer, J. Nemunaitis
2013Discover medicine28 citations
Semantic Scholar
Phase II clinical activity and tolerability of the SMAC-mimetic birinapant (TL32711) plus irinotecan in irinotecan-relapsed/refractory metastatic colorectal cancer.
N. Senzer, P. LoRusso, Lainie P. Martin, R. Schilder +6 more
201328 citations
Semantic Scholar
Three-year Follow up of GMCSF/bi-shRNAfurin DNA-transfected Autologous Tumor Immunotherapy (Vigil) in Metastatic Advanced Ewing's Sarcoma.
Maurizio Ghisoli, M. Barve, R. Mennel, C. Lenarsky +7 more
2016Molecular Therapy27 citations Open access
Semantic Scholar
A phase I study of birinapant (TL32711) combined with multiple chemotherapies evaluating tolerability and clinical activity for solid tumor patients.
R. Amaravadi, N. Senzer, Lainie P. Martin, R. Schilder +5 more
201326 citations
Semantic Scholar
Long-term follow-up of Phase 2A trial results involving advanced ovarian cancer patients treated with Vigil® in frontline maintenance
Johnathan Oh, M. Barve, N. Senzer, P. Aaron +9 more
2020Gynecologic Oncology Reports24 citations Open access
Semantic Scholar
Vertically integrated translational studies of PDX1 as a therapeutic target for pancreatic cancer via a novel bifunctional RNAi platform
James X. Wu, Shi-he Liu, Juehua Yu, Gui-Sheng Zhou +9 more
2014Cancer Gene Therapy24 citations Open access
Semantic Scholar
A multicenter phase 1 study of PX-866 and cetuximab in patients with metastatic colorectal carcinoma or recurrent/metastatic squamous cell carcinoma of the head and neck
D. Bowles, N. Senzer, D. Hausman, S. Peterson +4 more
2014Investigational new drugs23 citations
Semantic Scholar
Phase 1 study of N1,N11-diethylnorspermine (DENSPM) in patients with advanced hepatocellular carcinoma
L. Goyal, J. Supko, J. Berlin, L. Blaszkowsky +12 more
2013Cancer Chemotherapy and Pharmacology23 citations
Semantic Scholar
Phase I dose-escalation study of talimogene laherparepvec (T-VEC) for advanced pancreatic cancer (ca).
K. Chang, N. Senzer, K. Binmoeller, H. Goldsweig +1 more
201223 citations
Semantic Scholar
Chimeric Antigen Receptor T-Cell Therapy: Reach to Solid Tumor Experience
Matthew N. Metzinger, C. Verghese, D. Hamouda, A. Lenhard +5 more
2019Oncology21 citations
Semantic Scholar
Phase 1 Trial of Bi-shRNA STMN1 BIV in Refractory Cancer.
M. Barve, Zhao-Hui Wang, Padmasini Kumar, C. Jay +8 more
2015Molecular Therapy21 citations Open access
Semantic Scholar
31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): part two
C. Ager, M. Reilley, C. Nicholas, Todd Bartkowiak +496 more
2016Journal for ImmunoTherapy of Cancer18 citations Open access
Semantic Scholar
Bifunctional short hairpin RNA (bi-shRNA): design and pathway to clinical application.
D. Rao, N. Senzer, Zhao-Hui Wang, Padmasini Kumar +2 more
2013Methods in molecular biology17 citations
Semantic Scholar
KRAS mutant allele-specific expression knockdown in pancreatic cancer model with systemically delivered bi-shRNA KRAS lipoplex
D. Rao, Xiuquan Luo, Zhao-Hui Wang, C. Jay +5 more
2018PLoS ONE15 citations Open access
Semantic Scholar
Case Report: Immune-mediated Complete Response in a Patient With Recurrent Advanced Ewing Sarcoma (EWS) After Vigil Immunotherapy.
Maurizio Ghisoli, M. Rutledge, P. Stephens, R. Mennel +14 more
2017Journal of pediatric hematology/oncology15 citations
Semantic Scholar
Follow-up of bi-shRNA furin / GM-CSF Engineered Autologous Tumor Cell (EATC) Immunotherapy Vigil® in patients with advanced melanoma
M. Barve, J. Kuhn, J. Lamont, P. Beitsch +6 more
201615 citations Open access
Semantic Scholar

Frequent co-authors

Invite them to SciRah by sharing their profile.

J. Nemunaitis×30
Invite
J. Nemunaitis — researcher profile on SciRah
D. Rao×15
Invite
D. Rao — researcher profile on SciRah
M. Barve×14
Invite
M. Barve — researcher profile on SciRah
G. Wallraven×14
Invite
G. Wallraven — researcher profile on SciRah

×13

Invite

B. Pappen — researcher profile on SciRah

Padmasini Kumar×13

Invite

Padmasini Kumar — researcher profile on SciRah

Zhao-Hui Wang×11

Invite

Zhao-Hui Wang — researcher profile on SciRah

Invite

C. Bedell — researcher profile on SciRah

Invite

P. Maples — researcher profile on SciRah

Invite

C. Jay — researcher profile on SciRah

Invite

J. Kuhn — researcher profile on SciRah

F. Brunicardi×6

Invite

F. Brunicardi — researcher profile on SciRah